Protalix BioTherapeutics(PLX) - 2025 Q2 - Quarterly Report

For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 2 University Plaza Suite 100 Hackensack, NJ 07601 (Address of principal executive offices) (Zip Code) (201)-696-9345 001-33357 (Commission file number) PROT ...